Physician profile
Michael Alan Rees
NPI 1356337521
$1,947.00
in general payments reported to CMS, 2019-2025
15 companies · $23.88 in 2025
The $23.88 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2021: $370 · 2022: $72.47 · 2023: $898 · 2024: $362 · 2025: $23.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dornier Medtech America, INC | $417.92 | 2023 | Dornier Medtech |
| Sanofi-Aventis U.S. LLC | $351.00 | 2021 | |
| Astellas Pharma US INC | $199.98 | 2019-2023 | |
| Olympus America INC. | $173.31 | 2023 | Itind System, Soltive |
| Veloxis Pharmaceuticals, INC. | $158.05 | 2019-2023 | Envarsus |
| Procept Biorobotics Corporation | $143.75 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $122.78 | 2023 | Spaceoar Vue System - 10ml |
| Angiodynamics, INC. | $113.92 | 2024 | Nanoknife |
| Coloplast Corp | $104.39 | 2024 | |
| Axonics, INC. | $72.47 | 2022 | |
| Genzyme Corporation | $34.40 | 2023 | |
| Progenics Pharmaceuticals, INC. | $23.88 | 2025 | |
| Blue Earth Diagnostics | $19.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.